Physician profile
Edith M Dean
NPI 1609218726
$1,645.66
in general payments reported to CMS, 2019-2025
12 companies · $132 in 2025
The $132 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $849 · 2022: $438 · 2023: $169 · 2024: $57.49 · 2025: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $358.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $584.88 | 2021-2025 | Belbuca, Xtampza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $474.79 | 2021-2025 | Relistor |
| Amgen INC. | $176.26 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $137.85 | 2021-2024 | |
| Pfizer INC. | $75.37 | 2021-2025 | |
| Hikma Pharmaceuticals USA | $58.09 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $33.38 | 2021 | |
| Redhill Biopharma INC. | $28.92 | 2021-2022 | |
| Biodelivery Sciences International, INC. | $25.42 | 2021 | |
| Abbott Laboratories | $21.57 | 2025 | Eterna |
| Novartis Pharmaceuticals Corporation | $15.09 | 2021 | |
| Abbvie INC. | $14.04 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edith Dean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.